Uterine mesenchymal tumors: a review of selected topics

Soslow, Robert A.

doi:10.1016/j.mpdhp.2008.02.009

Cited by 9 publications

(5 citation statements)

References 135 publications

(118 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LMS tumor size was defined as the maximum dimension of the tumor at pathologic analysis. LMS histologic details included: degree of cellularity, grade (high grade or not high grade), presence of cellular atypia, degree of differentiation, number of mitotic figures per 10 high‐power fields, presence of necrosis, and degree of vascularity 18‐20…”

Section: Methodsmentioning

confidence: 99%

A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma

Zivanovic¹,

Jacks²,

Iasonos³

et al. 2011

Cancer

Self Cite

142

View full text Add to dashboard Cite

BACKGROUND The clinical course of patients with uterine leiomyosarcoma (LMS) is difficult to predict with the currently available categorical staging systems of the American Joint Committee on Cancer (AJCC) and the International Federation of Gynecology and Obstetrics (FIGO). The objective of the current study was to develop and validate a novel, clinically relevant, individualized prognostic model for patients with uterine LMS. METHODS Patients with uterine LMS who presented at the authors’ institution from 1982 to 2008 were analyzed. The nomogram model was chosen based on the clinical evidence and statistical significance of the predictors, including age at diagnosis, tumor size, histologic grade, uterine cervix involvement, extrauterine spread, distant metastases, and mitotic index. Five-year overall survival (OS) was the predicted endpoint. The concordance probability (CP) was used as a predictive accuracy measure and compared with the CP of current staging systems. The model was internally validated using 200 bootstrap samples to correct for over fitting. RESULTS One hundred eighty-five of 270 patients were eligible for the nomogram analysis. The median follow-up was 5.4 years, and the median OS was 3.75 years (95% confidence interval, 3-6 years). The CP of the newly developed nomogram was 0.67 (95% confidence interval, 0.63-0.72). This was superior to predictions based on AJCC and FIGO staging. The bootstrap-validated CP was 0.65 with good calibration accuracy. CONCLUSIONS The authors developed and internally validated a uterine LMS-specific nomogram to predict 5-year OS. This novel, individualized prognostic model outperforms traditionally used categorical staging systems and may be useful for patient counseling and for better selection of patients for adjuvant therapy trials.

show abstract

Section: Methodsmentioning

confidence: 99%

A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma

Zivanovic¹,

Jacks²,

Iasonos³

et al. 2011

Cancer

Self Cite

142

View full text Add to dashboard Cite

show abstract

“…Histologically, the defining feature of osteosarcoma is the production of neoplastic osteoid, bony matrix or both; although diagnosis may be challenging due to its focal nature 6. Osteoid outlines individual cells or less commonly solid sheets of osteoid may be present.…”

Section: Discussionmentioning

confidence: 99%

Primary uterine osteosarcoma presenting synchronously with bilateral breast carcinomas

Powell¹,

Barth

Todd

et al. 2014

BMJ Case Reports

View full text Add to dashboard Cite

Primary uterine sarcomas are infrequent neoplasms and most commonly leiomyosarcomas or endometrial stromal sarcomas. We report a rare case of primary uterine osteosarcoma discovered in a woman in her 60s following staging CT imaging for bilateral breast carcinomas. Examination of the subsequent hysterectomy specimen showed a tumour composed of malignant spindle cells and osteoclast-like giant cells associated with osteoid and neoplastic bone, in keeping with primary uterine osteosarcoma. Distinction of osteosarcoma from the more common carcinosarcoma is important due to the worse prognosis impacting on treatment decisions. In addition, synchronous presentation of this unusual tumour with bilateral breast carcinomas raises the possibility of a mutual genetic pathogenesis.

show abstract

“…Ki67 mitotic index is high (Figure 2E). Cyclin D1 is negative or focally positive [14]. However, in t (10;17), LGESS CD10 may be negative or weakly and focally positive [14][15][16][17][18][19][20][21][22][23][24][25][26][27].…”

Section: Immunohistochemistrymentioning

confidence: 99%

“…Cyclin D1 is negative or focally positive [14]. However, in t (10;17), LGESS CD10 may be negative or weakly and focally positive [14][15][16][17][18][19][20][21][22][23][24][25][26][27]. t (10,17) LGESSs are frequently negative for ER and PR too [15].…”

Section: Immunohistochemistrymentioning

confidence: 99%

Uterine Sarcomas: An Updated Overview

Zappacosta¹,

Fanfani²,

Zappacosta³

et al. 2018

Neoplasm

View full text Add to dashboard Cite

Uterine sarcomas (USs) account for 3-9% of uterine malignant neoplasia and about 5% of all gynaecologic malignancies. Despite their low prevalence, these tumors stimulate a great interest because of their aggressiveness, poor prognosis and high mortality rate. According to the last world health organization (WHO) classification and the International Federation of gynecology and obstetrics committee (FIGO) staging, USs are categorized as pure mesenchymal tumors (endometrial stromal sarcoma, leiomyosarcoma and undifferentiated uterine) and mixed tumors (carcinosarcoma and adenosarcoma). Due to their non-specific signs and symptoms, USs are commonly diagnosed in advanced stage, more often after surgery for a suspected leiomyoma. Although surgery followed by adjuvant therapies represent the common choices for USs, they show poor efficacy due to the early occurrence of metastasis, and the high resistance of tumors to radio-and chemotherapy. Presently, specific expression profiles and new cytotoxic agents are under investigation. In these reviews, we summarized clinical and pathological features, imaging characteristics, therapeutic approaches, genomic and molecular aberration associated with smooth muscle neoplasia (Part 1) and endometrial stromal neoplasia (Part 2); the goal is to understand the biology and the molecular signature of these tumors, in order to focus on their best management.

show abstract

Uterine mesenchymal tumors: a review of selected topics

Cited by 9 publications

References 135 publications

A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma

A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma

Primary uterine osteosarcoma presenting synchronously with bilateral breast carcinomas

Uterine Sarcomas: An Updated Overview

Contact Info

Product

Resources

About